Happy to share out latest preprint on SARS-CoV-2 within host diversity. Brief thread. biorxiv.org/content/10.110…
We've been interested in within-host diversity for some time. It's important for understanding how mutations accumulate over time (relevant for how variants arise). Important for understanding how likely it is for variants to transmit and potentially for inferring trx chains 2/x
We looked at inpatients and outpatients. First we measured viral load. Why? Cause we're interested. But it's also a big factor in looking at diversity within hosts (spoiler alert). Another important (unique?) thing in our study is we analyzed data by day from symptom onset 3/x
We then did a mixing study with variants at set frequencies (e.g. 10%, 5%, 2%) and varying input viral loads (10e4, 10e3) to benchmark our variant identification. As we've shown before, at lower viral loads, lots of false positive variants. This can be major issue in studies 4/x
So figured out a way to screen out false positives. We found that diversity is quite low (lower than some other reports). Most had only 1-3 minority variants at a 2% threshold. 5/x
A few had lots of minor variants. We're not sure why (have to read the preprint to see what we thought about). In general, there weren't that many variants over the time frame when most people transmit (so timed analysis key!). And most are <10% frequency. 6/x
Means it is likely uncommon for newly arising within-host variants to transmit (unless the bottleneck is really big). 7/x
Are variants shared among hosts? Sometimes. We found convergence in rare variant fraction across individuals - who were *unlikely* to be linked by transmission. So perhaps virus exploring similar solutions. These variants did not predict future consensus variants on GISAID 8/x
Are minority variants useful for transmission inference? Perhaps, but use with caution. We found shared variants in pairs with identical and non-identical consensus sequences. Some of whom did not have epi linkage. 9/x
Take home points: (1) QC is critical in within-host diversity studies. (2) Time-based analyses of diversification are informative. (3) No difference in diversity between inpatients and outpatients. (4) Challenges for studies of transmission.
Unfortunately very few - any? - studies that I’ve seen relating viral load to outcome stratify by day post infection or symptom onset. This is big issue (viral load varies by day and people vary in when they get tested in disease course for many reasons). nytimes.com/live/2020/12/2…
For example, here’s data from my lab showing viral load by day for outpatients (purple) vs hospitalized patients (green). All tests were on presentation. If you just look at viral load on presentation, outpatients were higher - they were just tested earlier.
H/t to @Kalee_Rumfelt in my lab who did the chart review. Most studies don’t have day post symptom onset because it’s hard to retrieve. You typically don’t get it in data pulls from EMR. You have to go into chart notes one by one.
Been thinking more about this piece from @kakape this morning and have some thoughts to share. So thought I'd do a Xmas eve thread about SARS-CoV-2/COVID19 and immunocompromised hosts. (1/x) sciencemag.org/news/2020/12/u…
I emphasize that I respect the stated opinions out there and don't have doubts about data or what they may show. Just feel there's a perspective missing from the conversation. What can I bring to conversation? I am an infectious disease physician and study virus evolution. (2/x)
I have taken care of patients with COVID19 who have a range of immunocompromising conditions. I have also published on within host evolutionary dynamics of viruses. We published a preprint in Sept and subsequent JID paper on long term evolution in lymphoma patient. (3/x)
With the news of this new variant and discussions of what it means for vaccines, keep thinking about this article from @SCOTTeHENSLEY and Yewdell (who very much needs a Twitter account). Short thread.
First question from ID docs and many virologists I know is “OMG, what does this mean for vaccines.” We grow up in this pathogen vs. immune system paradigm that is sometimes distracting from issues at play. (2)
Many variants have been reported to escape this serum or that monoclonal. But large scale selection of a variant at this point is probably not driven by immune system (just not that much immunity around). (3)